JP7493459B2 - 抗薬物抗体（ａｄａ）免疫アッセイにおける薬物標的干渉を軽減するための方法 - Google Patents

抗薬物抗体（ａｄａ）免疫アッセイにおける薬物標的干渉を軽減するための方法 Download PDF

Info

Publication number
JP7493459B2
JP7493459B2 JP2020564556A JP2020564556A JP7493459B2 JP 7493459 B2 JP7493459 B2 JP 7493459B2 JP 2020564556 A JP2020564556 A JP 2020564556A JP 2020564556 A JP2020564556 A JP 2020564556A JP 7493459 B2 JP7493459 B2 JP 7493459B2
Authority
JP
Japan
Prior art keywords
drug
target
ada
antibody
label
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020564556A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020014194A5 (https=
JP2021531448A5 (https=
JP2021531448A (ja
Inventor
サムナー， ジアーニ オリベイラ
ジーフア チェン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2021531448A publication Critical patent/JP2021531448A/ja
Publication of JPWO2020014194A5 publication Critical patent/JPWO2020014194A5/ja
Publication of JP2021531448A5 publication Critical patent/JP2021531448A5/ja
Priority to JP2024023599A priority Critical patent/JP2024045646A/ja
Application granted granted Critical
Publication of JP7493459B2 publication Critical patent/JP7493459B2/ja
Priority to JP2025179025A priority patent/JP2026012856A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020564556A 2018-07-10 2019-07-09 抗薬物抗体（ａｄａ）免疫アッセイにおける薬物標的干渉を軽減するための方法 Active JP7493459B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024023599A JP2024045646A (ja) 2018-07-10 2024-02-20 抗薬物抗体（ａｄａ）免疫アッセイにおける薬物標的干渉を軽減するための方法
JP2025179025A JP2026012856A (ja) 2018-07-10 2025-10-23 抗薬物抗体（ａｄａ）免疫アッセイにおける薬物標的干渉を軽減するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696016P 2018-07-10 2018-07-10
US62/696,016 2018-07-10
PCT/US2019/040950 WO2020014194A1 (en) 2018-07-10 2019-07-09 Methods for mitigating drug target interference in an anti-drug antibody (ada) immunoassay

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024023599A Division JP2024045646A (ja) 2018-07-10 2024-02-20 抗薬物抗体（ａｄａ）免疫アッセイにおける薬物標的干渉を軽減するための方法

Publications (4)

Publication Number Publication Date
JP2021531448A JP2021531448A (ja) 2021-11-18
JPWO2020014194A5 JPWO2020014194A5 (https=) 2022-07-11
JP2021531448A5 JP2021531448A5 (https=) 2022-07-11
JP7493459B2 true JP7493459B2 (ja) 2024-05-31

Family

ID=67544324

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020564556A Active JP7493459B2 (ja) 2018-07-10 2019-07-09 抗薬物抗体（ａｄａ）免疫アッセイにおける薬物標的干渉を軽減するための方法
JP2024023599A Pending JP2024045646A (ja) 2018-07-10 2024-02-20 抗薬物抗体（ａｄａ）免疫アッセイにおける薬物標的干渉を軽減するための方法
JP2025179025A Pending JP2026012856A (ja) 2018-07-10 2025-10-23 抗薬物抗体（ａｄａ）免疫アッセイにおける薬物標的干渉を軽減するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024023599A Pending JP2024045646A (ja) 2018-07-10 2024-02-20 抗薬物抗体（ａｄａ）免疫アッセイにおける薬物標的干渉を軽減するための方法
JP2025179025A Pending JP2026012856A (ja) 2018-07-10 2025-10-23 抗薬物抗体（ａｄａ）免疫アッセイにおける薬物標的干渉を軽減するための方法

Country Status (16)

Country Link
US (2) US12055551B2 (https=)
EP (1) EP3821255B1 (https=)
JP (3) JP7493459B2 (https=)
KR (1) KR102754704B1 (https=)
CN (1) CN112384808B (https=)
AU (1) AU2019301614B2 (https=)
BR (1) BR112020022912A2 (https=)
EA (1) EA202190237A1 (https=)
ES (1) ES2993989T3 (https=)
IL (1) IL277888B2 (https=)
MA (1) MA53130A (https=)
MX (1) MX2021000331A (https=)
MY (1) MY207418A (https=)
SG (1) SG11202011283TA (https=)
WO (1) WO2020014194A1 (https=)
ZA (1) ZA202006409B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022011336A (es) * 2020-03-17 2022-10-07 Regeneron Pharma Atenuacion de la interferencia de dianas en ensayo de anticuerpos antifarmacos.
CN114264814B (zh) * 2021-12-30 2025-03-14 苏州和锐生物科技有限公司 一种pd-1生物制剂的抗体检测试剂盒及制备方法
CN114324894A (zh) * 2021-12-31 2022-04-12 军科正源（北京）药物研究有限责任公司 一种检测贝伐珠单抗抗药性抗体的新型分析方法
CN114047343B (zh) * 2022-01-13 2022-05-31 美迪西普亚医药科技(上海)有限公司 双耐受型抗IgE单抗药物的免疫原性分析试剂盒及其使用方法和应用
JP2025514738A (ja) * 2022-04-19 2025-05-09 ソングァン メディカル ファンデーション 血液中の抗薬物抗体濃度測定による生物学的薬物に対する治療反応性の予測方法
WO2024044622A1 (en) * 2022-08-24 2024-02-29 Amgen Inc. Anti-drug antibody assays
CN115586337A (zh) * 2022-09-14 2023-01-10 杭州赛基生物科技有限公司 检测肿瘤伴随诊断相关因子的试剂盒及其制备方法
CN120239821A (zh) * 2022-09-23 2025-07-01 默沙东有限责任公司 中和抗体测定方法
CN115575468B (zh) * 2022-09-30 2025-08-26 华润生物医药有限公司 一种检测抗重组人GLP-1-Fc融合蛋白抗体的方法
CN115856322A (zh) * 2022-12-23 2023-03-28 同昕生物技术（北京）有限公司 用于抗奥马株单抗药物抗体检测的试剂及其应用
CN117805382B (zh) * 2024-02-28 2024-05-03 军科正源（北京）药物研究有限责任公司 检测抗利妥昔单抗中和抗体的方法
WO2025224166A1 (en) * 2024-04-23 2025-10-30 F. Hoffmann-La Roche Ag Anti-drug antibody assays

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005031353A1 (ja) 2003-09-26 2005-04-07 Matsushita Electric Industrial Co., Ltd. 免疫反応測定方法、ならびにそれに用いる試薬、キット、及び光学セル
JP2010527005A (ja) 2007-05-07 2010-08-05 ワイス・エルエルシー 抗炭水化物抗体によって生じるイムノアッセイにおける妨害の除去
US20150226758A1 (en) 2014-02-11 2015-08-13 Genzyme Corporation Assays for detecting the presence or amount of an anti-drug antibody
JP2016530495A (ja) 2013-07-04 2016-09-29 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856469A (en) 1973-01-02 1974-12-24 Syva Corp Interferant removal from amphetamine immunoassay
JPS55145690A (en) 1979-05-04 1980-11-13 Toyama Chem Co Ltd Novel penicillin and cephalosporin, and its salt
JPS6454356A (en) * 1987-08-26 1989-03-01 Meidensha Electric Mfg Co Ltd Method for suppressing non-specific adsorption of antibody to solid phase antigen
JPH02138872A (ja) * 1988-11-18 1990-05-28 Asahi Chem Ind Co Ltd 癌関連物質のための免疫測定方法
WO2009022001A1 (en) 2007-08-16 2009-02-19 Novartis Ag Improvement of drug tolerance in immunogenicity testing
DK2723769T4 (da) * 2011-06-23 2022-09-05 Ablynx Nv Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
WO2017096262A1 (en) * 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
US20190145985A1 (en) 2017-11-10 2019-05-16 BioAgilytix Labs, LLC Method for eliminating target interference
AU2018374469B2 (en) 2017-11-29 2022-06-16 F. Hoffmann-La Roche Ag Target interference suppressed anti-drug antibody assay
MX2022011336A (es) * 2020-03-17 2022-10-07 Regeneron Pharma Atenuacion de la interferencia de dianas en ensayo de anticuerpos antifarmacos.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005031353A1 (ja) 2003-09-26 2005-04-07 Matsushita Electric Industrial Co., Ltd. 免疫反応測定方法、ならびにそれに用いる試薬、キット、及び光学セル
JP2010527005A (ja) 2007-05-07 2010-08-05 ワイス・エルエルシー 抗炭水化物抗体によって生じるイムノアッセイにおける妨害の除去
JP2016530495A (ja) 2013-07-04 2016-09-29 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ
US20150226758A1 (en) 2014-02-11 2015-08-13 Genzyme Corporation Assays for detecting the presence or amount of an anti-drug antibody

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Karen Liao，Inhibition of interleukin-5 induced false positive anti-drug antibody responses against mepolizumab through the use of a competitive blocking antibody，Journal of Immunological Methods，2017年，Vol.441，Page.15-23
Keguan Chen，False-positive immunogenicity responses are caused by CD20+ B cell membrane fragments in an anti-ofatumumab antibody bridging assay，Journal of Immunological Methods，2013年，Vol.394，Page.22-31
Sheng Dai，Development of a Method That Eliminates False-Positive Results due to Nerve Growth Factor Interference in the Assessment of Fulranumab Immunogenicity，The AAPS Journal，2014年，Vol.16 No.3，Page.464-477

Also Published As

Publication number Publication date
CN112384808A (zh) 2021-02-19
IL277888B1 (en) 2024-12-01
MY207418A (en) 2025-02-26
US20240353423A1 (en) 2024-10-24
ZA202006409B (en) 2025-07-30
KR20210031854A (ko) 2021-03-23
AU2019301614B2 (en) 2025-11-20
JP2026012856A (ja) 2026-01-27
JP2024045646A (ja) 2024-04-02
EP3821255B1 (en) 2024-08-28
BR112020022912A2 (pt) 2021-02-23
KR102754704B1 (ko) 2025-01-20
MA53130A (fr) 2021-05-19
US12055551B2 (en) 2024-08-06
WO2020014194A1 (en) 2020-01-16
IL277888B2 (en) 2025-04-01
IL277888A (en) 2020-11-30
CN112384808B (zh) 2024-10-11
ES2993989T3 (en) 2025-01-15
MX2021000331A (es) 2021-03-25
EP3821255A1 (en) 2021-05-19
CA3098206A1 (en) 2020-01-16
AU2019301614A1 (en) 2020-10-22
US20200018770A1 (en) 2020-01-16
JP2021531448A (ja) 2021-11-18
SG11202011283TA (en) 2020-12-30
EA202190237A1 (ru) 2021-04-15

Similar Documents

Publication Publication Date Title
JP7493459B2 (ja) 抗薬物抗体（ａｄａ）免疫アッセイにおける薬物標的干渉を軽減するための方法
US12566186B2 (en) Assays for detecting the presence or amount of an anti-drug antibody
CA3098206C (en) Methods for mitigating drug target interference in an anti-drug antibody (ada) immunoassay
EA051332B1 (ru) Способы уменьшения мешающего влияния мишени лекарственного средства в иммунологическом анализе на антитела к лекарственному средству (ada)
EA045148B1 (ru) Способы уменьшения мешающего влияния мишени лекарственного средства в иммунологическом анализе на антитела к лекарственному средству (ada)
WO2022202876A1 (ja) Ｉ型コラーゲンｃ末端テロペプチドの免疫学的分析方法
HK40002296A (en) Assays for detecting the presence or amount of an anti-drug antibody
HK40002296B (en) Assays for detecting the presence or amount of an anti-drug antibody
HK1231962A1 (en) Assays for detecting the presence or amount of an anti-drug antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220630

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240501

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240521

R150 Certificate of patent or registration of utility model

Ref document number: 7493459

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150